Nivolumab plus PAI-1 inhibitor combined therapy for unresectable advanced melanoma: Phase II clinical trial

被引：0
|
作者：
Fujimura, T. [1 ]
Yoshino, K. [2 ]
Kato, H. [3 ]
Fukushima, S. [4 ]
Otsuka, A. [5 ]
Matsushita, S. [6 ]
Fujisawa, Y. [7 ]
Ishizuki, S. [8 ]
Kambayashi, Y. [1 ]
Asano, Y. [1 ]
机构：
[1] Tohoku Daigaku, Dermatol, Sendai, Miyagi, Japan
[2] Canc Inst Hosp Japanese Fdn Canc Res, Dermato Oncol, Tokyo, Japan
[3] Nagoya Shiritsu Daigaku, Dermatol, Nagoya, Aichi, Japan
[4] Kumamoto Daigaku, Dept Dermatol, Kumamoto, Kumamoto, Japan
[5] Kinki Daigaku, Dept Dermatol, Higashiosaka, Osaka, Japan
[6] Kokuritsu Byoin Kiko Kagoshima Iryo Ctr, Dermato Oncol, Kagoshima, Kagoshima, Japan
[7] Ehime Daigaku, Dermatol, Matsuyama, Ehime, Japan
[8] Tsukuba Daigaku, Dermatol, Tsukuba, Ibaraki, Japan
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
1194
引用
收藏
页码：S205 / S205
页数：1
相关论文
共 50 条
  • [21] Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
    Mimura, Kosaku
    Ogata, Takashi
    Yoshimoto, Yuya
    Yoshida, Daisaku
    Nakajima, Shotaro
    Sato, Hisashi
    Machida, Nozomu
    Yamada, Takanobu
    Watanabe, Yohei
    Tamaki, Tomoaki
    Fujikawa, Hirohito
    Inokuchi, Yasuhiro
    Hayase, Suguru
    Hanayama, Hiroyuki
    Saze, Zenichiro
    Katoh, Hiroyuki
    Takahashi, Fumiaki
    Oshima, Takashi
    Suzuki, Yoshiyuki
    Kono, Koji
    COMMUNICATIONS MEDICINE, 2023, 3 (01):
  • [22] Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
    Kosaku Mimura
    Takashi Ogata
    Yuya Yoshimoto
    Daisaku Yoshida
    Shotaro Nakajima
    Hisashi Sato
    Nozomu Machida
    Takanobu Yamada
    Yohei Watanabe
    Tomoaki Tamaki
    Hirohito Fujikawa
    Yasuhiro Inokuchi
    Suguru Hayase
    Hiroyuki Hanayama
    Zenichiro Saze
    Hiroyuki Katoh
    Fumiaki Takahashi
    Takashi Oshima
    Yoshiyuki Suzuki
    Koji Kono
    Communications Medicine, 3
  • [23] A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
    Postow, Michael A.
    Knox, Susan J.
    Goldman, Debra A.
    Elhanati, Yuval
    Mavinkurve, Vikram
    Wong, Phillip
    Halpenny, Darragh
    Reddy, Sunil K.
    Vado, Kenya
    McCabe, Danielle
    Ramirez, Kristen Aufiero
    Macri, Mary
    Schwarzenberger, Paul
    Ricciardi, Toni
    Ryan, Aileen
    Venhaus, Ralph
    Momtaz, Parisa
    Shoushtari, Alexander N.
    Callahan, Margaret K.
    Chapman, Paul B.
    Wolchok, Jedd D.
    Subrahmanyam, Priyanka B.
    Maecker, Holden T.
    Panageas, Katherine S.
    Barker, Christopher A.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 3193 - 3201
  • [24] Trial in progress: clinical trial of nivolumab combined with ipilimumab followed by nivolumab monotherapy as first-line therapy of patients with stage III (unresectable) or stage IV melanoma: CheckMate 401
    Dummer, R.
    Gutzmer, R.
    Corrie, P.
    Millward, M.
    Murzhenko, A.
    Maio, M.
    MELANOMA RESEARCH, 2016, 26 : E43 - E43
  • [25] Development of the combination therapy of anti-PD1 antibody with PAI-1 inhibitors in advanced melanoma patients
    Fujimura, T.
    Ohuchi, K.
    Kambayashi, Y.
    Hidaka, T.
    Asano, Y.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S257 - S257
  • [26] Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Namba, Yoshinobu
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2020, 47 (11): : 1257 - 1266
  • [27] A phase II trial of nivolumab in combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness.
    Sussman, Tamara A.
    Wei, Wei
    Hobbs, Brian
    Diaz-Montero, C. Marcela
    Ni, Ying
    Arbesman, Joshua
    Ko, Jennifer S.
    Gastman, Brian
    Funchain, Pauline
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma:: a randomized phase II trial
    Reichle, Albrecht
    Vogt, Thomas
    Coras, Brigitte
    Terheyden, Peter
    Neuber, Klaus
    Trefzer, Uwe
    Schultz, Erwin
    Berand, Anna
    Broecker, E. B.
    Landthaler, Michael
    Andreesen, Reinhard
    MELANOMA RESEARCH, 2007, 17 (06) : 360 - 364
  • [29] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [30] Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
    T. M. L. Tong
    M. K. van der Kooij
    F. M. Speetjens
    A. R. van Erkel
    R. W. van der Meer
    J. Lutjeboer
    E. L. van Persijn van Meerten
    C. H. Martini
    R. W. M. Zoethout
    F. G. J. Tijl
    C. U. Blank
    M. C. Burgmans
    E. Kapiteijn
    Trials, 23
12345